Branded Legacy, Inc. Finalizes Transformative Acquisition of Bio Legacy Evaluative Group (f/k/a Menlo Health), Unlocking Explosive Growth Potential in Biotech and Drug Delivery
Branded Legacy (OTC: BLEG) has completed the acquisition of Bio Legacy Evaluative Group (formerly Menlo Health) in an all-stock deal valued at $1.5 million in Preferred D stock. The transaction positions BLEG in the biotech and medical device sectors, focusing on addiction treatment and vaccine delivery solutions.
Key highlights include a two-year lock-up period for the Preferred D stock, which converts upon Bio Legacy reaching a $40 million valuation, and a $1 million R&D commitment post-OTCQB uplisting. Bio Legacy's patented intranasal naloxone device targets a market projected to grow from $371 million in 2022 to $1.16 billion by 2032. The company projects potential revenue of $183.3 million by Year 5.
Following the acquisition, Amin Janmohamed assumes the CEO role, with Dr. Kristian Thorlund as Chairman, bringing extensive biotech expertise to drive growth and innovation.
Branded Legacy (OTC: BLEG) ha completato l'acquisizione di Bio Legacy Evaluative Group (precedentemente Menlo Health) in un'operazione interamente in azioni valutata a $1.5 million in Preferred D stock. L'accordo posiziona BLEG nei settori biotech e dei dispositivi medici, con un focus sui trattamenti per la dipendenza e sulle soluzioni per la somministrazione di vaccini.
I punti chiave includono un periodo di lock-up di due anni per le azioni Preferred D, che si convertono al raggiungimento da parte di Bio Legacy di una valutazione di $40 million, e un impegno di $1 million per R&D dopo la quotazione su OTCQB. Il dispositivo intranasale brevettato di Bio Legacy per la somministrazione di naloxone punta a un mercato stimato in crescita da $371 million nel 2022 a $1.16 billion entro il 2032. L'azienda prevede ricavi potenziali di $183.3 million entro il quinto anno.
A seguito dell'acquisizione, Amin Janmohamed assume il ruolo di CEO, mentre Dr. Kristian Thorlund ricopre la carica di Chairman, apportando vasta esperienza nel settore biotech per guidare crescita e innovazione.
Branded Legacy (OTC: BLEG) ha completado la adquisición de Bio Legacy Evaluative Group (anteriormente Menlo Health) en una operación íntegramente en acciones valorada en $1.5 million in Preferred D stock. La transacción sitúa a BLEG en los sectores de biotecnología y dispositivos médicos, con enfoque en tratamientos para la adicción y soluciones de administración de vacunas.
Los aspectos clave incluyen un periodo de lock-up de dos años para las acciones Preferred D, que se convierten cuando Bio Legacy alcance una valoración de $40 million, y un compromiso de $1 million en I+D tras la cotización en OTCQB. El dispositivo intranasal patentado de naloxona de Bio Legacy apunta a un mercado proyectado a crecer de $371 million en 2022 a $1.16 billion en 2032. La compañía proyecta ingresos potenciales de $183.3 million para el quinto año.
Tras la adquisición, Amin Janmohamed asume el cargo de CEO y Dr. Kristian Thorlund la presidencia, aportando amplia experiencia en biotecnología para impulsar crecimiento e innovación.
Branded Legacy (OTC: BLEG)는 Bio Legacy Evaluative Group(구 Menlo Health)을 전액 주식으로 교환하는 방식으로 인수했으며, 거래 가치는 $1.5 million in Preferred D stock입니다. 이번 거래로 BLEG는 중독 치료와 백신 전달 솔루션에 중점을 둔 바이오텍 및 의료기기 분야에 진입하게 되었습니다.
주요 내용으로는 2년 간의 락업 기간이 적용되는 Preferred D 주식이 있으며, 이는 Bio Legacy가 $40 million의 밸류에이션에 도달하면 전환됩니다. 또한 OTCQB 상장 후 $1 million의 연구개발(R&D) 약속이 포함되어 있습니다. Bio Legacy의 특허받은 비강용(코) 날록손 장치는 2022년 $371 million에서 2032년 $1.16 billion으로 성장할 것으로 예상되는 시장을 겨냥하며, 회사는 5년차에 $183.3 million의 잠재 매출을 전망하고 있습니다.
인수 후 Amin Janmohamed가 CEO로 취임하고, Dr. Kristian Thorlund가 의장으로 합류하여 성장과 혁신을 이끌 폭넓은 바이오테크 경험을 제공합니다.
Branded Legacy (OTC: BLEG) a finalisé l'acquisition de Bio Legacy Evaluative Group (anciennement Menlo Health) dans le cadre d'une transaction entièrement en actions, évaluée à $1.5 million in Preferred D stock. Cette opération place BLEG dans les secteurs de la biotechnologie et des dispositifs médicaux, axés sur les traitements des addictions et les solutions d'administration des vaccins.
Parmi les points clés figurent une période de lock-up de deux ans pour les actions Preferred D, qui se convertissent lorsque Bio Legacy atteint une valorisation de $40 million, ainsi qu'un engagement de $1 million en R&D après l'inscription sur l'OTCQB. Le dispositif intranasal breveté de naloxone de Bio Legacy vise un marché estimé passer de $371 million en 2022 à $1.16 billion d'ici 2032. La société prévoit un chiffre d'affaires potentiel de $183.3 million d'ici la cinquième année.
À la suite de l'acquisition, Amin Janmohamed prend le poste de CEO, tandis que Dr. Kristian Thorlund devient président, apportant une vaste expertise en biotechnologie pour stimuler la croissance et l'innovation.
Branded Legacy (OTC: BLEG) hat die Übernahme von Bio Legacy Evaluative Group (ehemals Menlo Health) in einem vollständig aktienbasierten Deal im Wert von $1.5 million in Preferred D stock abgeschlossen. Die Transaktion positioniert BLEG in den Bereichen Biotech und Medizintechnik mit Schwerpunkt auf Suchtbehandlung und Impfstoff-Applikationslösungen.
Zu den wichtigsten Punkten zählt eine zwei Jahre dauernde Lock-up-Phase für die Preferred D-Aktien, die sich umwandeln, sobald Bio Legacy eine Bewertung von $40 million erreicht, sowie eine Verpflichtung zu $1 million in F&E nach dem Uplisting aufs OTCQB. Das patentierte intranasale Naloxon-Gerät von Bio Legacy zielt auf einen Markt, der voraussichtlich von $371 million im Jahr 2022 auf $1.16 billion bis 2032 wächst. Das Unternehmen prognostiziert potenzielle Umsätze von $183.3 million bis zum Jahr 5.
Nach der Übernahme übernimmt Amin Janmohamed die Rolle des CEO, während Dr. Kristian Thorlund den Vorsitz einnimmt und umfangreiche Biotech-Expertise einbringt, um Wachstum und Innovation voranzutreiben.
- All-stock acquisition structure preserves cash and aligns interests with shareholders
- Target market for naloxone device projected to reach $1.16B by 2032 with 11.9% CAGR
- Potential revenue of $183.3M by Year 5
- Strong leadership team with extensive biotech and medical expertise
- Two-year lock-up period and valuation-based conversion protects against dilution
- $1M R&D commitment post-uplisting to accelerate product development
- Revenue generation delayed until Q1 2027 with product launch
- Significant regulatory hurdles ahead with clinical trials required
- Success dependent on achieving OTCQB uplisting and $0.01 share price for R&D funding
- High execution risk in competitive biotech market
Acquisition Poised to Drive Substantial Shareholder Value Through Innovative Technologies, Projected Multi-Million Revenues, and Strategic Leadership Alignment: Amin Janmohamed Steps Up as CEO and Dr. Kristian Thorlund as Chairman to Spearhead Long-Term Success
VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a dynamic diversified holdings company at the forefront of health and wellness innovation, is excited to announce the completion of its game-changing acquisition of Bio Legacy Evaluative Group, formerly Menlo Health ("Bio Legacy"). This strategic move, executed under an Acquisition Agreement dated July 28, 2025, propels Branded Legacy into the lucrative biotech and medical device arenas, targeting urgent global health challenges like the addiction epidemic and vaccine distribution inefficiencies. For shareholders, this acquisition represents a pivotal opportunity for enhanced value creation, with cutting-edge technologies set to capture significant market share in rapidly expanding sectors.
Demonstrating a profound commitment to long-term growth and integration, Bio Legacy has rebranded from Menlo Health to Bio Legacy Evaluative Group, aligning seamlessly with Branded Legacy's vision. This rebranding underscores the team's dedication to building a unified powerhouse focused on sustainable expansion and enduring success within the public markets. Shareholders can rest assured: this is a team built for the long haul, laser-focused on delivering real, measurable growth, uplisting milestones, and substantial returns through disciplined execution and innovation.
Key Transaction Highlights: Fueling Shareholder Prosperity
The Acquisition Agreement delivers a shareholder-friendly structure designed to maximize upside potential:
- All-Stock Deal for Alignment: Branded Legacy acquired full ownership of Bio Legacy's equity, assets, IP, and operations in exchange for
$1.5 million in Preferred D stock, valued at the prior day's common stock closing price—ensuring interests are fully aligned with existing shareholders. - Incentivized Performance Milestones: The Preferred D stock features a two-year lock-up period and converts only upon Bio Legacy reaching a
$40 million valuation via independent appraisal, tying rewards directly to value creation and protecting shareholder dilution. - Robust R&D Investment: A
$1 million R&D commitment kicks in post-uplisting to OTCQB and a sustained$0.01 share price, accelerating Bio Legacy's pipeline and positioning Branded Legacy for exponential revenue growth. - Swift Execution: Closed on July 31, 2025, following a July 17, 2025 LOI, Bio Legacy now operates as a wholly-owned subsidiary, integrating seamlessly to hit the ground running.
Bio Legacy: A Powerhouse of Innovation Poised for Market Domination
Under the leadership of CEO Amin Janmohamed—a seasoned pharmacist, clinical trials researcher, and visionary executive—Bio Legacy boasts an elite advisory team including Stanford's Prof. Eran Bendavid, MD (Research Lead), UMass's Prof. Sonal Singh, MD (Medical Lead and Drug Policy Expert), Order of Canada honoree Prof. Martin Schechter, MD, PhD (Epidemiology Lead), addiction specialist Dr. Scott MacDonald, MD, and startup veteran Blake Daly, MBA (Business Development Lead). Dr. Kristian Thorlund is Chairman of the group.
Bio Legacy's revolutionary patented all-in-one intranasal naloxone device tackles the addictions crisis head-on by slashing costs, boosting dosing accuracy, and simplifying delivery—overcoming barriers in a market exploding from
Aggressive Roadmap to Revenue:
- Q3 2025: Manufacturing prototyping
- Q4 2025: Full patent filings
- 2026: Clinical trials and results
- Q1 2027: Naloxone device market launch
In average growth scenarios, Bio Legacy could generate up to
Leadership and Vision: Committed to Your Success
Following the closing of the acquisition, Amin Janmohamed will assume the role of CEO and Dr Kristian Thorlund as Chairman of Branded Legacy, Inc., infusing fresh expertise to navigate this high-growth trajectory. "This is more than an acquisition—it's a commitment to transformative impact," said Jeffery Robison, outgoing CEO of Branded Legacy. "Bio Legacy's innovations will catalyze our evolution into a biotech leader, delivering outsized returns for our loyal shareholders."
Amin Janmohamed echoed, "We're all-in for the long term. By aligning under Branded Legacy, our world-class team is empowered to innovate relentlessly, achieve uplisting goals, and build a legacy of growth that rewards shareholders every step of the way. Together, we'll turn groundbreaking ideas into market realities and substantial value."
This acquisition fortifies Branded Legacy's biotech prowess, with a Form 8-K filing forthcoming to detail the agreement.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) is a diversified holdings company dedicated to acquiring and growing innovative businesses in the health, wellness, and technology sectors. With a focus on strategic partnerships and shareholder value, Branded Legacy aims to deliver cutting-edge solutions that address real-world challenges.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.
Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the value of Branded Legacy's acquisition of Bio Legacy Evaluative Group?
When will BLEG's naloxone device enter the market?
Who are the new leaders of Branded Legacy (BLEG) following the acquisition?
What is the market potential for BLEG's naloxone device?
What are the key terms of BLEG's Preferred D stock issued for the acquisition?
